2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-110022
    GW1929 hydrochloride 1217466-21-1 98%
    GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential.
    GW1929 hydrochloride
  • HY-110029
    Paroxetine maleate 64006-44-6 98%
    Paroxetine maleate is a potent and selective inhibitor of SSRI. Paroxetine maleate is used in generalized anxiety disorder, post traumatic stress disorder, premenstrual dysphoric disorder and chronic headache research.
    Paroxetine maleate
  • HY-110048
    O-2545 hydrochloride 874745-43-4 98%
    O-2545 hydrochloride is a highly potent, water-soluble CB1/CB2 receptor agonist (with Ki values of 1.5 and 0.32 nM for CB1 and CB2 respectively), can be used for epilepsy, pain, multiple sclerosis research.
    O-2545 hydrochloride
  • HY-110056
    NBI 35965 hydrochloride 1782228-59-4 98%
    NBI 35965 hydrochloride is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki value of 4 nM and a pKi value of 8.5. NBI 35965 hydrochloride does not inhibit CRF2. NBI 35965 hydrochloride reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC50 values of 7.1 and 6.9, respectively. NBI 35965 hydrochloride shows anxiolytic effects.
    NBI 35965 hydrochloride
  • HY-110070
    DL-AP4 sodium 1263093-79-3 98%
    DL-AP4 sodium (2-Amino-4-phosphonobutyric acid sodium) is an agonist for metabotropic glutamate receptors (mGluR). DL-AP4 sodium binds to mGluR4, activates the signaling pathway that is negatively correlated with adenylate cyclase, and inhibits the Forskolin (HY-15371)-induced production of cAMP. DL-AP4 sodium is also an inhibitor for ON channel, that reduces the sensitivity of photoreceptors to brightness changes.
    DL-AP4 sodium
  • HY-110142
    Thermopsidine 492-02-4 98%
    Thermopsidine (CC4) is a selective partial agonist at α4β2/α6β2 nAChR with EC50 values of 2.2 μM target α4β2.
    Thermopsidine
  • HY-11017R
    Rivastigmine tartrate (Standard) 129101-54-8 98%
    Rivastigmine (tartrate) (Standard) is the analytical standard of Rivastigmine (tartrate). This product is intended for research and analytical applications. Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.
    Rivastigmine tartrate (Standard)
  • HY-11018R
    Risperidone (Standard) 106266-06-2 98%
    Risperidone (Standard) is the analytical standard of Risperidone. This product is intended for research and analytical applications. Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively.
    Risperidone (Standard)
  • HY-110202
    MRS5698 1377273-00-1 98%
    MRS5698 is a selective Gi protein-coupled A3 adenosine receptor (A3AR) agonist, with Kis of approximately 3 nM for human and mouse A3AR, respectively. MRS5698 can be used for the research of pain and psoriasis.
    MRS5698
  • HY-110230
    Flupirtine-d4 hydrochloride 1324717-75-0 98%
    Flupirtine-d4 (D 9998-d4) hydrochloride is the deuterium labeled Flupirtine. Flupirtine(D 9998) hydrochloride is a selective neuronal potassium channel opener that also has NMDA receptor antagonist properties.
    Flupirtine-d4 hydrochloride
  • HY-110303
    Xanthine amine congener dihydrochloride 1962928-23-9 98%
    Xanthine amine congener dihydrochloride (XAC dihydrochloride) is a potent Adenosine A1 receptor and A2 receptor antagonist with IC50 values of 1.8 and 114 nM, respectively. Xanthine amine congener acts as a convulsant agent in mice model.
    Xanthine amine congener dihydrochloride
  • HY-110304
    NPEC-caged-LY379268 1315379-62-4 98%
    NPEC-caged-LY379268 is a type II mGluR agonist.
    NPEC-caged-LY379268
  • HY-110310
    NGD 98-2 hydrochloride 1780390-58-0 98%
    NGD 98-2 hydrochloride is an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist
    NGD 98-2 hydrochloride
  • HY-110330
    R 1485 dihydrochloride 98%
    R 1485 is a 5-HT6 receptor antagonist.
    R 1485 dihydrochloride
  • HY-110351
    BGC-20-1531 hydrochloride 1962928-26-2 98%
    BGC 20-1531 (PGN 1531) hydrochloride is a potent and selective prostanoid EP4 receptor antagonist, with a pKb of 7.6. BGC 20-1531 hydrochloride has the potential for the research of migraine headache.
    BGC-20-1531 hydrochloride
  • HY-110366
    WAY-181187 oxalate 1883548-85-3 98%
    WAY-181187 (SAX-187) oxalate is a potent and selective full 5-HT6 receptor agonist with a Ki of 2.2 nM and an EC50 of 6.6 nM. WAY-181187 oxalate mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist.
    WAY-181187 oxalate
  • HY-11052A
    Trap-101 hydrochloride 1216621-00-9 98%
    Trap-101 hydrochloride is a potent, selective and competitive antagonist of NOP receptors over classical opioid receptors. Trap-101 stimulates GTPγ35S binding to CHOhNOP membranes with pKi values of 8.65, 6.60, 6.14 and <5 for NOP, μ-, κ-, and δ-opioid receptors, respectively. Trap-101 attenuates motor deficits in a rat model of parkinson's disease and can be used for the research of nervous system diseases.
    Trap-101 hydrochloride
  • HY-111000
    BNC-1 96335-59-0 98%
    BNC-1 is an Elk-1 activator that can promote phosphorylation and activation of Elk-1.
    BNC-1
  • HY-111011
    CR 665 acetate 958873-83-1 98%
    CR 665 (JNJ 38488502) acetate is a kappa-opioid agonist that may effectively treat visceral pain by activating receptors on afferent nerves within the gut. CR 665 acetate exhibits peripheral selectivity, differentiating its pharmacokinetic profile from that of non-selective opioids like oxycodone. CR 665 acetate has demonstrated a beneficial effect on visceral pain tolerance thresholds without the delayed analgesic response characteristic of opioids that penetrate the brain. CR 665 acetate is proposed for use in managing postoperative pain due to its pain-relieving properties.
    CR 665 acetate
  • HY-111025
    Ectylurea 95-04-5 98%
    Ectylurea, a N-acylurea, can be used in studies of tension and anxiety symptoms, has no effect on the autonomic nervous system, and has no convulsive, analgesic or antispasmodic activity in animals.
    Ectylurea
Cat. No. Product Name / Synonyms Application Reactivity